Home › Pathophysiology › Tumor Staging and Tumor Markers

Tumor Staging and Tumor Markers

Q: What does the G parameter mean in an oncological diagnosis?

The G parameter (Grade) represents the histological grade of the tumor, reflecting the degree of cellular differentiation: Gx — Grade cannot be assessed.G1 — Well-differentiated (low grade).G2 — Moderately differentiated (intermediate grade).G3 — Poorly differentiated (high grade).

Q: Why are tumor markers needed if histological examination is already performed?

Markers complement histology. They are essential for monitoring treatment efficacy, predicting recurrences, and identifying high-risk patient groups.

Q: Why do fetal antigens appear in gastrointestinal or liver cancers?

Malignant cells can dedifferentiate and revert to an embryonic program of synthesis, producing fetal antigens normally restricted to embryogenesis (e.g., alpha-fetoprotein or carcinoembryonic antigen).

Q: How to differentiate carcinoma from sarcoma using markers?

Monoclonal antibodies against intermediate filaments are used. Carcinomas (epithelial tumors) express keratins, while sarcomas (mesenchymal tumors) express vimentin.

For medical students2 min readUpdated 2026-10-10

Tumor markers are specific antigens expressed on the cell surface or intracellularly, the levels of which increase significantly during malignant growth. Combined with the TNM staging system, they allow clinicians to determine patient prognosis, select treatment strategies, and identify the primary origin of a tumor even from isolated metastases.

TNM SystemEvaluates the primary tumor size, lymph node involvement, and distant metastases

CD AntigensGlycoproteins and glycolipids used for immunophenotyping

Occult Primary2–10% of patients present with metastases from an unidentified primary tumor

Fetal AntigensSynthesized by tumors, although normally active only during embryonic development

Purpose and Principles of Tumor Staging

The evaluation of a malignant process is based on four key criteria: the true size of the neoplasm, the extent of surrounding tissue invasion, regional lymph node involvement, and the presence of distant metastases.

This information is critical for two main objectives:

Prognostication. While stage I carries a favorable prognosis, the outlook progressively worsens with higher stages.
Treatment Planning. Staging helps select optimal therapeutic modalities, their combinations, and the correct sequence of local and systemic interventions.

In global oncological practice, the TNM system is the standard for describing anatomical disease extent:

T (Tumor) — characterizes the primary tumor itself, its dimensions, and depth of tissue invasion.
N (Node) — indicates the degree of regional lymph node involvement.
M (Metastasis) — confirms the presence and extent of distant metastases.

What Are Tumor Markers?

Tumor markers (or clusters of differentiation, CD) are specific surface or cytoplasmic antigens of glycoprotein or glycolipid nature. During malignant transformation, the expression of these differentiation antigens increases manifold.

Clinically, markers serve as a crucial adjunct to traditional histology. They help identify high-risk groups, monitor treatment efficacy, and predict potential recurrences.

Several groups of markers exist:

Specific Cellular Markers. Malignant cells often retain the ability to produce substances typical of their normal precursors. For example, prostate adenocarcinoma exhibits high prostatic acid phosphatase activity and PSA (prostate-specific antigen) expression.
Fetal Antigens (Embryonic Antigens). Tumors may synthesize compounds normally produced only during embryogenesis. These include alpha-fetoprotein (found in hepatocellular carcinoma, teratoblastoma, and pediatric hepatoblastoma) and carcinoembryonic antigen (typical of gastrointestinal tract cancers).

Additionally, markers of neuroblastoma (an embryonal tumor) are notable. These typically express Phox2b and C-kit (neural crest stem cell antigens), Sox10 and AP2α (immature glial cell markers), and NSE (neuron-specific enolase, an intracellular enzyme of the central nervous system).

Cytoskeleton and Detecting Occult Metastases

One of the most precise methods in modern diagnostics is the detection of cytoskeletal markers using monoclonal antibodies against intermediate filaments. This approach accurately identifies the cell lineage of a tumor:

Keratins serve as markers for epithelial cells and are consistently retained in carcinomas.
Vimentin is a marker of mesenchymal origin actively expressed in sarcomas. Important nuance: if anti-vimentin antibodies are detected in a carcinoma, they localize exclusively to the stroma (blood vessel walls) rather than the tumor parenchyma itself.

The Occult Primary Tumor Problem In clinical practice, 2% to 10% of patients present with metastases while the primary site remains undetected. Furthermore, in 15%–20% of such cases, the source is never found even at autopsy.

The solution to this diagnostic dilemma is immunophenotyping of metastatic cells using enzyme-linked immunosorbent assay (ELISA) or immunohistochemistry. This precisely establishes the tissue origin of the metastasis and guides appropriate therapy even when the primary tumor remains occult.

Mnemonic

The acronym TNM is easily remembered by its first letters: T — Tumor, N — Node, M — Metastasis.

Frequently asked questions

In which malignancies is alpha-fetoprotein (AFP) detected?

AFP is recognized as a tumor marker in the following conditions:

Hepatocellular carcinoma.
Hepatoblastoma in children.
Teratoblastoma.
Germ cell tumors of the ovary, specifically yolk sac tumors; elevated AFP is also noted in embryonic carcinoma, polyembryoma, and immature teratomas.
Mediastinal germ cell tumors, where AFP is part of the specific marker panel, raising suspicion for non-seminomatous germ cell tumors.
Biliary tract cancers, where AFP is included in the standard panel of tumor markers.

What fetal antigens act as tumor markers?

Fetal or embryonic antigens are substances expressed by tumors that are normally synthesized only during embryonic development. Examples include:

Alpha-fetoprotein (AFP) — hepatocellular carcinoma, teratoblastoma, pediatric hepatoblastoma.
Carcinoembryonic antigen (CEA) — gastrointestinal cancers.
PSA (prostate-specific antigen) — prostate cancer.

What does the G parameter mean in an oncological diagnosis?

The G parameter (Grade) represents the histological grade of the tumor, reflecting the degree of cellular differentiation:

Gx — Grade cannot be assessed.
G1 — Well-differentiated (low grade).
G2 — Moderately differentiated (intermediate grade).
G3 — Poorly differentiated (high grade).

What is the proliferation index Ki-67 used for?

Ki-67 is a proliferation marker utilized in several clinical contexts:

In breast cancer, Ki-67 helps distinguish luminal A and luminal B subtypes, with high Ki-67 identifying the subgroup that benefits most from chemotherapy.
In gastrointestinal neuroendocrine neoplasms following R0 resection, subsequent management depends on Grade and Ki-67: G3 with Ki-67 ≤ 55% may undergo observation or chemotherapy, whereas G3 with Ki-67 > 55% or neuroendocrine carcinoma (NEC) mandates chemotherapy.
In adrenocortical pathology, Ki-67 serves as a robust negative prognostic indicator included in the Helsinki scoring system to predict metastatic potential.
In biliary adenoma, a low proliferation index of Ki-67 < 10% is noted as a benign feature.

Why are tumor markers needed if histological examination is already performed?